Atherosclerotic renovascular disease (ARD) is a common condition in which the atherosclerotic narrowing of renal arteries may lead to renin-dependent hypertension, progressive renal dysfunction, and/or recurrent pulmonary edema. It typically occurs in high-risk patients with coexistent vascular disease elsewhere. Consequently, most patients with ARD are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. The incidence of renal artery thrombosis is less than 1% per year. The risk of chronic renal replacement therapy is 18 times lower than that of a major cardiovascular event.

Stenting aims at reducing blood pressure (BP), stabilizing or improving renal function, and preventing cardiovascular and renal events in patients with ARD. Controlled trials comparing medication plus stenting to medication alone, medication plus surgery, or medication plus angioplasty without stenting provided disappointing results. Most patients undergoing stenting to treat hypertension associated with ARD, still require antihypertensive agents after the procedure because the reduction in BP following stenting is modest, and because several antihypertensive agents, such as renin-angiotensin antagonists or β-blockers, are needed to prevent cardiovascular and renal events even in patients with normalized BP. Two recent trials compared renal outcome in ARD patients provided with medication plus stenting with that in ARD patients supplied with medication alone. Their results have shown that stenting does not preserve renal function. Improvements in revascularization techniques did not alter BP or renal outcomes of angioplasty. Compared with angioplasty alone, stenting plus protection devices and intravenous platelet inhibition did not improve renal function. The main explanation for these negative results is that ARD involves downstream renal parenchymal lesions that cannot be improved by revascularization. A trial comparing the effects of medication alone (including an angiotensin II receptor antagonist) and medication plus renal artery stenting on cardiovascular outcomes is currently underway.

Stenting for ARD does not improve BP and kidney function better than medical treatment. Besides, it is associated with frequent complications. Thirty-one of the 226 stented patients (13.7%) in the trials summarized in the table suffered major complications as defined by current criteria. Stable patients with ARD should be treated first with medical management. Available trials did not include unstable patients with uncontrollable hypertension or with pulmonary edema. It is therefore possible, yet unproved, that renal artery stenting is useful in patients with ARD and refractory hypertension or heart failure, or that it is preferable to abstention in ARD patients given a renin-angiotensin antagonist. With or without revascularization, medical therapy using hypolipidemic and antiplatelet agents and renin-angiotensin antagonists is required for the prevention of renal and cardiovascular events in patients with ARD.

Does stenting for atherosclerotic renovascular disease improve blood pressure and kidney function better than medical treatment?

Pierre F. Plouin, Laurence Amar

Paris Descartes University, Hypertension Unit, Hôpital Européen Georges Pompidou, ESH Hypertension Excellence Center, Paris, France

Correspondence to:
Prof. Pierre F. Plouin, MD, PhD,
Hypertension Unit, Hôpital Européen
Georges Pompidou,
20 rue Leblanc,
75908 Paris Cedex 15, France,
phone: +33‑1‑56‑09‑37‑73,
tel.: +33‑1‑56‑09‑37‑91,
email: pierre‑francois.plouin@regp.aphp.fr
Received: August 27, 2009.
Accepted: August 27, 2009.
Conflict of interest: none declared.
Copyright by Medycyna Praktyczna, Kraków 2009

612 POLSKIE ARCHIWUM MEDYCyny Wewnętrznej 2009; 119 (10)
Does stenting for atherosclerotic renovascular disease...

### References


---

### Table

<table>
<thead>
<tr>
<th>First author</th>
<th>Main selection criteria</th>
<th>Stenting procedure (number of patients)</th>
<th>Control (number of patients)</th>
<th>Patients with major complications stent: control</th>
<th>BP at follow-up, mmHg stent:control</th>
<th>Renal function at follow-up stent:control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Van de Ven⁸, 1999</td>
<td>uni- or bilateral stenosis ≥50% plus lateralized renography or a rise in Cr ≥20% on ACEI</td>
<td>stent alone (42)</td>
<td>angioplasty alone (42)</td>
<td>10:10</td>
<td>160/90:165/90</td>
<td>Cr 140:134</td>
</tr>
<tr>
<td>Cooper⁹, 2008</td>
<td>uni- or bilateral stenosis ≥50%</td>
<td>stent + abciximab (25) / stent + protection device (22) / stent + both (25)</td>
<td>stent alone (28)</td>
<td>1/1/3:3</td>
<td>NR</td>
<td>58/52/54:52</td>
</tr>
<tr>
<td>Balzer¹⁰, 2009</td>
<td>uni- or bilateral ostial stenosis ≥70%</td>
<td>stent alone (22)</td>
<td>surgery (27)</td>
<td>3:2</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Bax¹¹, 2009</td>
<td>uni- or bilateral stenosis ≥50%, GFR 15–80 ml/min, stable BP</td>
<td>stent alone (62)</td>
<td>medication (74)</td>
<td>10:0</td>
<td>151/77:155/79</td>
<td>10:16 patients with endpoint¹ GFR 50:46</td>
</tr>
</tbody>
</table>

---

a The primary endpoint was the percentage of patients with a 20% or greater decrease in GFR during a 2-year follow-up.

Abbreviations: ACEI – angiotensin-converting enzyme inhibitor, BP – blood pressure, Cr – creatinine (µmol/l), GFR – glomerular filtration rate (ml/min), NR – not reported